Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.53 |
| ▸ | GBA1 | P04062 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14884374 | 0.85 | KIT (0.51) | KITGBA1CKS1BSKP1SKP2 | |
| SCHEMBL3523230 | 0.84 | KIT (0.47) | KITGBA1CKS1BSKP1SKP2 | |
| SCHEMBL9778388 | 0.79 | PARP1 (0.52) | KITTNKSPARP1PARP2ALDH1A1 | |
| SCHEMBL29468210 | 0.79 | JAK2 (0.52) | CHRM2CHRM4CHRM1CHRM3CNR1 | |
| SCHEMBL14737550 | 0.79 | JAK2 (0.52) | CHRM2CHRM4CHRM1CHRM3CNR1 | |
| SCHEMBL9778394 | 0.79 | PARP1 (0.49) | TNKSPARP1PARP2ALDH1A1MAPT | |
| SCHEMBL9778596 | 0.78 | MEN1 (0.64) | KITTNKSPARP1PARP2ALDH1A1 | |
| SCHEMBL10469604 | 0.78 | HTR1A (0.58) | KITGBA1DTYMK | |
| SCHEMBL3337275 | 0.78 | CHRM2 (0.49) | KITGBA1CHRM2CHRM4CHRM1 | |
| SCHEMBL3673763 | 0.77 | TRPV1 (0.53) | KITGBA1CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022078971-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2022-04-21 | — | — | WO | disclosed |
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2014-11-27 | — | — | US | disclosed |
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-7696229-B2 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696229-B2 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696229-B2 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1984351-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION | 2008-02-14 | — | — | US | disclosed |
| WO-2007098418-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007098418-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD4, CD47 | KIT 2728/4885GBA1 2679/4885CHRM2 3335/4885 |
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3B, HTR1B | KIT 416/4885GBA1 2990/4885CHRM2 159/4885 |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | HTR6, HTR3B, HTR1B | KIT 416/4885GBA1 2990/4885CHRM2 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.